+91-8668442535
Home / Healthcare / Induced Pl

Induced Pluripotent Stem Cell (IPSC) Market By Process (Manual, Automated) By Product (Instruments/Devices, Automated Platforms, Consumables & Kits, Services) By Workflow (Reprogramming, Cell Culture, Cell Characterization/Analysis, Engineering, Others) By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others) By End Use (Research & Academic Institutes, Biotechnology & Pharmaceutical) - Growth, Future Prospects, And Competitive Analysis, 2016 -2028

About this report

The global Induced Pluripotent Stem Cell (IPSC) Market report explores the critical analysis of the Induced Pluripotent Stem Cell (IPSC) industry using key parameters. The report consists of investment strategies, the need for investments in the Induced Pluripotent Stem Cell (IPSC) industry, and the multiple benefits for the investors. Importantly, this report sets out major changes in the global technical regulations for the Induced Pluripotent Stem Cell (IPSC) industry, as well as how economic and non-economic barriers are helping the Induced Pluripotent Stem Cell (IPSC) market grow. Moreover, the report analyzes the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, and Tornado analysis. Key technological developments and other analyses such as porter's five forces analysis, PESTEL analysis, value chain analysis, etc.

induced-pluripotent -stem-cell-ipsc-market

Key Highlights of the report

How are the major segments performing in the Induced Pluripotent Stem Cell (IPSC) Market?

In 2021, with a revenue share of 78%, the manual IPSC production process segment dominated the global market. By simply improving the manual processes that are frequently employed to reprogramme patient cells, the IPSC generation process can be made more economical and effective. The segment's supremacy is a result of its usefulness for manufacturing several IPSC lines concurrently.

Cell culture was the predominant workflow sector in 2021, with a revenue share of more than 37%. It is anticipated that it will continue to grow at a constant CAGR during the forecast period. Cell culture is a key procedure in producing IPSC since investigations of stem cell activity and differentiation in development is challenging, expensive, and time-consuming.

Which region dominated the Induced Pluripotent Stem Cell (IPSC) Market?

In 2021, North America dominated the market, accounting for more than 52% of total sales. The market growth in the area was facilitated by robust business models in the U.S. and Canada. Additionally, businesses are funding IPSC-related research initiatives. For instance, by providing funding for IPSC research and its translation into clinical applications, the California Institute for Regenerative Medicine (CIRM) supports research institutes. Additionally, the Regenerative Medicine Program has been launched by the National Health Institute (NIH). The purpose of this program is to provide tools that will encourage the use of IPSCs for therapeutic purposes. Additionally, the RPM encourages sharing IPS cell lines for use in clinical and lab research.

What is the competitive environment of the Induced Pluripotent Stem Cell (IPSC) Market?

The IPSC industry's competitive environment offers information on the total economic profit made by suppliers and businesses, the sales and revenues produced in this sector, the IPSC market share globally, the business organization overview, the introduction of new products, and the opportunities for the IPSC market. Key players are focused on enhancing their product portfolio through alliances and partnerships with other significant companies and expanding their products through significant R&D. For instance, in January 2021, Bristol Myers Co. awarded USD 6 million to Evotec SE for their collaboration on IPS cell-based neuroscience. This collaboration should aid in the discovery of disease-modifying therapies for a variety of neurogenerative illnesses. Axol Biosciences expanded its service offering in October 2020 by introducing Multi-Electrode Array (MEA) screening for human IPSC-derived cells.

Executive Summary

What are the Technical developments being developed in the Induced Pluripotent Stem Cell (IPSC) Market?

IPSC are cells with the ability to differentiate into any adult or germ cell under particular growing conditions. As a result, all major organs today have developed functional parenchymal cells. The creation of tissue constructs based on developmental biology and tissue engineering methodology has increased significantly in recent years, paving the way for the use of IPSCs to create tissues and glands that can be utilized to replace failing or defective parts of any important organs.

Which are the key investments by the players in the Induced Pluripotent Stem Cell (IPSC) Market?

Induced pluripotent stem cell suppliers are increasing their investments in research and development to advance their offerings in stem cell therapies which are gaining popularity for treating multiple chronic diseases. For instance, in April 2022, TreeFrog Therapeutics, a biotechnology firm focused on making affordable stem cell therapies, announced the launch of a grant worth US$ 100,000. The Stem Cell SpaceShot Grant will be open to PhD-level scientists and students to advance stem cell biology research and promote scientific discoveries. Bristol Myers Co. awarded USD 6 million to Evotec SE in January 2021 for collaboration in IPS cell-based neuroscience. This collaboration should aid in the discovery of disease-modifying therapies for a variety of neurogenerative illnesses. Axol Biosciences expanded its service offering in October 2020 by introducing Multi-Electrode Array (MEA) screening for human IPSC-derived cells.

Some of the major players in the market are Lonza; Axol Biosciences Ltd.; Evotec; Hitachi Ltd.; Merck KGaA; REPROCELL Inc.; Fate Therapeutics; Thermo Fisher Scientific, Inc.; StemCellFactory III; and Applied StemCell Inc.

What are the Major Driving Factors for the Induced Pluripotent Stem Cell (IPSC) Market?

The creation of an endless supply of any human cell required for therapeutic reasons is made possible by induced pluripotent stem cells (IPSCs), which are obtained from skin or blood cells and reprogrammed to revert to a pluripotent state similar to that of an embryo. The ability of induced pluripotent stem cells to produce any cell or tissue needed by the body to fight or treat diseases like leukemia, spinal cord injury, heart disease, and diabetes is the main factor driving the trend toward their use. Another benefit is that IPSCs can be produced using the same patient's tissue who will receive the transplant, preventing immunological rejection. Increased research funding, an increase in the number of genomics projects, and an increase in the application of genome editing in customized medicine are further factors boosting the market's expansion. However, the public's misperception of genetic research is likely to impede market expansion.

What Major Risks for the Induced Pluripotent Stem Cell (IPSC) Market?

The market's expansion may be hampered by high IPSC production costs, tumorigenicity, immunogenicity, and heterogeneity. Over time in in-vitro culture, the IPS cells may display chromosomal instability, loss of heterozygosity, copy number variation, and genetic instability. Additionally, IPSCs are often grown and generated using a feeder layer method, which can result in significant lot-to-lot variability, safety and regulatory problems, and issues with process scalability.

Which is the key Process in the Induced Pluripotent Stem Cell (IPSC) Market?

With a revenue share of 78.13% in 2021, the manual IPSC production process segment dominated the global market. By simply improving the manual processes that are frequently employed to reprogramme patient cells, the IPSC generation process can be made more economical and effective. Converting somatic cells into IPS involves several frequently used manual techniques and devices and is primarily done by hand. The manual IPSC creation technique necessitates trained workers who can identify appropriate colonies and efficiently complete various generating activities. The segment's supremacy is a result of its usefulness for manufacturing several IPSC lines concurrently.

The fastest CAGR is anticipated in the automated IPSC production process between 2021 and 2028. The demand for automation systems is rising due to the growing need for minimally variable, large-scale, reproducible stem cells and differentiated progeny generation. To facilitate research on various disorders, such as diabetes, cardiovascular disease, and neurodegenerative diseases, several nations have launched IPSC line collection projects.

How is the Induced Pluripotent Stem Cell (IPSC) Market performing in regions?

North America dominated with more than 52% of the market's total sales in 2021. Strong business concepts in the United States and Canada helped the local market flourish. Additionally, businesses are supporting research projects connected to IPSC. For instance, the California Institute for Regenerative Medicine (CIRM) assists research institutes by sponsoring IPSC studies and their conversion into clinical applications. Additionally, the National Health Institute has started the Regenerative Medicine Program. This program's goal is to offer resources that promote the use of IPSCs for therapeutic purposes. The RPM also promotes the exchange of IPS cell lines for use in clinical and laboratory research.

Over the forecast period, stable growth is anticipated in Europe. Research on IPSCs in this area is advancing thanks to the creation of the EBiSC. The mission of the EBiSC is to provide research-grade, quality-controlled IPS cell lines, data, and disease-relevant cell services. Additionally, it is a non-profit IPS cell lines bank for business and academia to provide dependable, superior tools for developing cutting-edge medicines.

Companies are entering into collaborations to increase the availability of their IPSC-derived medicines, which will, in turn, fuel regional research efforts. To create human IPSC-derived medicines for the treatment of ophthalmic disorders, Hopstem Biotechnology and Neurophth Therapeutics joined forces in June 2021. Hopstem Biotechnology got an upfront payment and development milestone payments under this strategic collaboration to create a candidate cell product to treat degenerative retinal degeneration.

What is the regulatory landscape for the Induced Pluripotent Stem Cell (IPSC) Market?

Patients have a great deal of optimism about developing individualized pluripotent stem cells for research and potential therapeutics. However, before they can be employed as therapeutic reagents, such cells must overcome severe technical and regulatory difficulties. Here, we examine two potential sources of customized pluripotent stem cells: induced pluripotent stem cells (IPSCs), produced through direct reprogramming of adult somatic cells, and nuclear transfer-derived embryonic stem cells (NT-ESCs). In certain ways, the regulatory obstacles faced by stem cells obtained from fertilization-produced embryos are much higher than those faced by stem cells from both sources of individualized pluripotent stem cells.

What is the Market Size of the Induced Pluripotent Stem Cell (IPSC) regarding value?

The global Induced Pluripotent Stem Cell (IPSC) Market is anticipated to grow at a substantial CAGR of 8.4% in the upcoming years. The global Induced Pluripotent Stem Cell (IPSC) industry was estimated to be worth USD 2,194.2 million in 2021 and was expected to be worth USD 3,560.02 million by 2028.

What are the major players planning for the future of the Induced Pluripotent Stem Cell (IPSC) Market?

Key players are concentrating on enhancing their product portfolio through alliances and partnerships with other significant companies and expanding their products through significant R&D. For instance, in January 2021, Bristol Myers Co. awarded USD 6 million to Evotec SE for their collaboration on iPS cell-based neuroscience. This collaboration should aid in the discovery of disease-modifying therapies for a variety of neurogenerative illnesses. Axol Biosciences expanded its service offering in October 2020 by introducing Multi-Electrode Array (MEA) screening for human iPSC-derived cells.

Segmentation of Global Induced Pluripotent Stem Cell (IPSC) Market-

Global Induced Pluripotent Stem Cell (IPSC) Market – By Process

  • Manual
  • Automated

 Global Induced Pluripotent Stem Cell (IPSC) Market – By Product

  • Instruments/Devices
  • Automated Platforms
  • Consumables & Kits
  • Services

Global Induced Pluripotent Stem Cell (IPSC) Market – By Workflow

  • Reprogramming
  • Cell Culture
  • Cell Characterization/Analysis
  • Engineering
  • Others

Global Induced Pluripotent Stem Cell (IPSC) Market – By Application

  • Drug Development and Discovery
  • Regenerative Medicine
  • Toxicology Studies
  • Others

Global Induced Pluripotent Stem Cell (IPSC) Market – By End Use

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & clinics

Global Induced Pluripotent Stem Cell (IPSC) Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Frequently asked questions about the global induced pluripotent stem cell (IPSC) market.

The rapid introduction of COVID-19 in 2020 caused significant shifts in international healthcare trends and altered how markets operated in these unheard-of circumstances. However, researchers looked at the possibility of using induced pluripotent stem cells to treat coronavirus infections throughout the pandemic.

North America accounted for the highest share in the global induced pluripotent stem cell (IPSC) market.

Increasing cases of chronic diseases and the development of automated IPSC production processes are the major factors driving the market's growth.

Manual production process had a major share in 2021 with around 78% of the market revenue share. Besides, it is also projected to witness the fastest growth.

The cell culture segment had a major share in the global market in 2021.

Induced Pluripotent Stem Cell (IPSC) Market Scope

Report Attribute Details
Market Value in 2021 USD 2,194.2 million
Market Value in 2028 USD 3,560.02 million
CAGR 8.4%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2022
Category:  Healthcare
Report ID:   60714
Report Format:   PDF
Pages:   120
Rating:    4.6 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support